Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine  by Mutomba, Martha C. et al.
Regulation of the activity of caspases by L-carnitine and
palmitoylcarnitine
Martha C. Mutombaa;1, Hua Yuana;1, Mary Konyavkoa, Souichi Adachia,
Christopher B. Yokoyamaa, Victoria Esserb, J. Denis McGarryb, Bernard M. Babiora,
Roberta A. Gottlieba;*
aDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
bDepartments of Internal Medicine and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Received 25 May 2000; revised 28 June 2000; accepted 30 June 2000
Edited by Vladimir Skulachev
Abstract L-Carnitine facilitates the transport of fatty acids into
the mitochondrial matrix where they are used for energy
production. Recent studies have shown that L-carnitine is capable
of protecting the heart against ischemia/reperfusion injury and
has beneficial effects against Alzheimer’s disease and AIDS. The
mechanism of action, however, is not yet understood. In the
present study, we found that in Jurkat cells, L-carnitine inhibited
apoptosis induced by Fas ligation. In addition, 5 mM carnitine
potently inhibited the activity of recombinant caspases 3, 7 and 8,
whereas its long-chain fatty acid derivative palmitoylcarnitine
stimulated the activity of all the caspases. Palmitoylcarnitine
reversed the inhibition mediated by carnitine. Levels of carnitine
and palmitoyl-CoA decreased significantly during Fas-mediated
apoptosis, while palmitoylcarnitine formation increased. These
alterations may be due to inactivation of L-oxidation or to an
increase in the activity of the enzyme that converts carnitine to
palmitoylcarnitine, carnitine palmitoyltransferase I (CPT I). In
support of the latter possibility, fibroblasts deficient in CPT I
activity were relatively resistant to staurosporine-induced
apoptosis. These observations suggest that caspase activity may
be regulated in part by the balance of carnitine and
palmitoylcarnitine. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Apoptosis is a form of cell death characterized by a se-
quence of events which result in the elimination of the cell
without release of its contents into the extracellular space [1].
This form of cell death is mediated by a group of highly
speci¢c cysteine proteases known as cysteine aspartic acid
speci¢c proteases (caspases). Under normal circumstances,
caspases exist as dormant zymogens, but when a cell receives
a death signal, caspases are activated through limited proteol-
ysis. Once activated, e¡ector caspases both activate other cas-
pases and cleave a host of cellular substrates, leading to the
characteristic morphological changes associated with apopto-
sis, as for example DNA fragmentation and condensation of
cellular organelles.
Proteolysis is an irreversible event and thus there must be
strict control of caspase activation in order to prevent inap-
propriate cell death. Indeed, it has been shown that caspase
activity is regulated by a number of interacting proteins, in-
cluding IAPs (inhibitors of apoptosis proteins) [2^4] and Flips
(FADD-like ICE inhibitory proteins) [5]. Caspases have also
been shown to be a¡ected by small molecules, notably nitric
oxide, which acts at the critical thiol residue in the catalytic
center [26].
Apoptosis has been implicated in the etiology of several
human diseases, including Alzheimer’s [6], AIDS [7] and is-
chemic injury [8,9]. Interestingly, a number of studies and
clinical trials have shown that L-carnitine has therapeutic ef-
fects in these conditions [10^12], raising the possibility that it
may be acting as an anti-apoptotic agent. Carnitine is a nat-
urally occurring quaternary amine zwitterion that facilitates
the transport of fatty acids into the mitochondria for L-oxi-
dation. Its concentration varies from 0.1 to a few mM, de-
pending on the tissue [13]. Highest concentrations of carnitine
are found in cardiac and skeletal muscle, concentrations ex-
ceeding 3 mM having been reported in human skeletal muscle
[14]. Of the total carnitine, over 90% is found in the cytosol,
with only a small fraction found within the mitochondrial
pool [15].
In this study, we investigated the e¡ects of carnitine and
palmitoylcarnitine on caspase activity. We show that the levels
of these key components of fatty acid metabolism are altered
during apoptosis and that they can modulate caspase activity.
In this study, we investigated whether the bene¢cial e¡ects
of L-carnitine were a result of its anti-apoptotic activity. Our
results showed that L-carnitine protected Jurkat cells against
Fas-mediated apoptosis and inhibited the activity of recombi-
nant caspases. Its anti-caspase activity could be a mechanism
for its anti-apoptotic e¡ect.
2. Materials and methods
2.1. Materials
L-Carnitine, D-carnitine, betaine, taurine, trimethyllysine, acetylcar-
nitine, choline, phosphorylcholine chloride and 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) were ob-
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tained from Sigma (St. Louis, MO, USA). Palmitoylcarnitine was
obtained from Fluka (Milwaukee, WI, USA). The compounds were
used at the indicated concentrations in the assays of recombinant
caspase activity. Where noted, L-carnitine was added to whole cells
at di¡erent concentrations, 1 h prior to addition of anti-Fas antibody.
2.2. Cell culture and induction of apoptosis
Jurkat cells were obtained from ATCC and maintained in RPMI
1640 with 5% fetal bovine serum and 2 mM L-glutamine. The cells
were used when they had grown to 1U106 cells/ml. To induce apo-
ptosis, the cells were incubated with 500 ng/ml anti-Fas antibody
(clone CH-11, Kamiya Biomedical Company, WA, USA) in serum-
free medium at a cell density of 4U107 cells/ml. Apoptosis was as-
sessed by acridine orange staining and scoring of nuclei showing
chromatin condensation and/or nuclear fragmentation. Between 150
and 200 cells were scored for each condition. Fibroblasts from con-
trols and carnitine palmitoyltransferase (CPT) I de¢cient patients were
obtained from Dr. Jean-Marie Saudubray of the Department of Pe-
diatrics, Hopital des Enfants Malades, Paris, France [16,17]. Both cell
lines were maintained in DMEM with 10% fetal bovine serum. For
induction of apoptosis, cells were seeded in a 96-well plate with 10 000
cells/well in 100 Wl of medium. The cells were left overnight at 37‡C to
attach, then treated with di¡erent concentrations of staurosporine for
varying periods of time. Percentage of cell death was detected using
the cell impermeant DNA dye YOPRO-1 (Molecular Probes, Eugene,
OR, USA) as described [18], using a Microplate Fluorescence Reader
(Bio-tek Instruments, Inc., Winooski, VT, USA), Exmax/Emmax
(nm) = 480/520.
2.3. Preparation of cell fractions
Whole cell lysates were prepared from cells (5U107 for each assay)
incubated with anti-Fas antibody for the required time and then
washed once in phosphate-bu¡ered saline (PBS: 137 mM NaCl,
8 mM KCl, 10 mM Na2HPO4, 2 mM K2PO4, pH 7.4). Cells were
resuspended in 250 Wl MF bu¡er (20 mM PIPES, pH 6.8, 100 mM
sucrose, 1 mM EGTA, 1 mM EDTA, 10 mM dithiothreitol (DTT),
25 mM KCl, 10 mM NaCl, 1 g/l bovine serum albumin and 5%
Percoll), supplemented with 25 Wg/ml leupeptin, 20 Wg/ml pepstatin
and 1 mM PMSF. Cells were then disrupted by sonication and the
lysate cleared by centrifugation at 14 000Ug for 30 min at 4‡C. Super-
natants were used for assays.
For making fractions, after anti-Fas treatment, cells (1U109) were
washed in 10 ml MA bu¡er (100 mM sucrose, 1 mM EGTA, 20 mM
MOPS pH 7.4, 1 g/l bovine serum albumin), then resuspended in 6 ml
ME bu¡er (20 mM PIPES, pH 6.8, 100 mM sucrose, 1 mM EGTA,
1 mM EDTA, 10 mM DTT, 1 g/l bovine serum albumin, 5% Percoll),
supplemented with leupeptin, pepstatin and PMSF. The cells were
disrupted by nitrogen cavitation as previously described [19], and
nuclei and unbroken cells removed by two centrifugations at
1200Ug. The postnuclear supernatant was centrifuged at 14 000Ug
for 30 min at 4‡C and both the postmitochondrial supernatant and
mitochondrial pellet recovered. S100 cytosol was prepared by ultra-
centrifugation of the postmitochondrial supernatant at 100 000Ug for
30 min at 4‡C. The mitochondrial pellet was washed in two changes of
0.5 ml sucrose wash bu¡er (0.25 M sucrose, 10 mM Tris^HCl pH 7.4,
1 mM EGTA), then resuspended in sucrose bu¡er (0.3 M sucrose, 10
mM Tris^HCl pH 7.4 and 1 mM EGTA), with protease inhibitors.
2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS^PAGE) and Western analysis
One-dimensional SDS^PAGE was carried out using a 4^20% gra-
dient running gel (Novex, San Diego, CA, USA). Western blotting
was performed using 30 Wg protein for each sample or as noted in the
¢gure legends. Caspase 2 antibody was from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA), caspase 3 antibody was from PharMin-
gen (San Diego, CA, USA) and caspase 9 antibody was a gift from
Dr. Guy Salvesen (Burnham Institute, La Jolla, CA, USA). The anti-
body against poly(ADP-ribose) polymerase (PARP) was from Boehr-
inger Mannheim (Germany).
2.5. Caspase activity assays
Caspase activity was measured at room temperature using a method
adapted from Stennicke and Salvesen [20]. Brie£y, in a Corning 96-
well plate, 20 ng of recombinant caspase 3 or 7, or 200 ng recombi-
nant caspase 8 (PharMingen, San Diego, CA, USA) was added to
caspase assay bu¡er (20 mM PIPES, pH 6.8, 100 mM NaCl, 10
mM DTT, 1 mM EDTA, 10% sucrose) and 100 WM of the substrate
N-acetyl-DEVD p-nitroanilide (DEVD-pNA) in a ¢nal volume of 120
Wl. The plate was placed in a Molecular Devices UVmax Kinetic
Microplate Reader (Molecular Devices, Menlo Park, CA, USA) and
left to equilibrate for 5^10 min at room temperature. Hydrolysis of
the substrate was followed at 405 nm for 60 min. Caspase activity in
cell lysates was measured in the same way using 100 Wg protein in a
¢nal volume of 150 Wl.
2.6. Caspase cleavage of endogenous substrates
To determine the e¡ect of carnitine or palmitoylcarnitine on the
cleavage of endogenous substrates by the recombinant caspases, 100
Wg of S100 cytosols from non-apoptotic cells was incubated with 20
ng of either recombinant caspase 3 or 8 for 2 h at 37‡C in the presence
of increasing concentrations of either compound. For autoactivation
of caspase 9, S100 cytosols (100 Wg) were incubated with 10 Wg/ml
horse heart cytochrome c and 0.1 WM dATP for 2 h at 37‡C in the
presence or absence of carnitine and palmitoylcarnitine. Samples (30
Wg protein) were subjected to SDS^PAGE and Western analysis, then
the blots were immunostained with anti-caspase antibodies. Alterna-
tively, 20 ng of recombinant caspase 3 was preincubated with palmi-
toylcarnitine in caspase assay bu¡er for 10 min at room temperature,
before addition of increasing concentrations of either carnitine or
palmitoyl-CoA. 2 Wg of human recombinant PARP (Trevigen, Gai-
thersburg, MD, USA) was added in a ¢nal volume of 25 Wl and the
mixtures incubated at 37‡C for 25 min. The samples were then sub-
jected to SDS^PAGE and Western analysis.
2.7. CPT and hydrolase assays
To measure CPT I activity in ¢broblasts, we used the method of
McMillin [21]. This distinguishes between CPT I and CPT II activ-
ities, based on the fact that CPT I is located in the outer mitochon-
drial membrane and so can interact with substrates after digitonin
permeabilization of whole cells, while CPT II is within the mitochon-
drial inner membrane and cannot utilize substrates until the mem-
brane is solubilized with detergent (Triton X-100), which also inacti-
vates CPT I. We con¢rmed that CPT I activity revealed by digitonin
permeabilization could be inhibited to greater than 95% by 100 WM
malonyl-CoA (data not shown). Cells were resuspended in permeabi-
lization bu¡er (140 mM KCl, 20 mM NaCl, 5 mM MgCl2, 1 mM
EGTA, 0.56 mM CaCl2, 40 mM HEPES pH 7.0, 0.1% bovine serum
albumin, 5 mM ATP, 5 WM KCN) containing 10 WM digitonin. Cells
were incubated at 37‡C for 10 min, then resuspended in bu¡er without
digitonin and 300 WM of unlabeled carnitine containing 1 WCi
[3H]carnitine (Sigma, St. Louis, MO, USA) as tracer was added.
Samples were incubated for 10 min at 37‡C and 30 WM palmitoyl-
CoA was added to initiate the reaction. Samples were incubated for
another 20 min and the reaction stopped by the addition of 1.5 ml
butanol-saturated 0.73 M HCl. [3H]Palmitoylcarnitine was extracted
with 1 ml n-butanol, while [3H]carnitine remained in the aqueous
phase. [3H]Palmitoylcarnitine was quanti¢ed by scintillation counting.
2.8. Palmitoyl-CoA measurements in whole cells
Jurkat cells (3U108) were induced to undergo apoptosis with 500
ng/ml anti-Fas IgM or incubated in parallel, then washed once in ice-
cold PBS before being added dropwise to liquid nitrogen. The frozen
cell pellets were ground with a te£on pestle, then resuspended in 1 ml
isopropanol for lipid extraction. 5 nCi of 14C-labeled palmitoyl-CoA
was added in order to monitor e⁄ciency of recovery during the sub-
sequent steps. Samples were extracted as described [22] and analyzed
by high performance liquid chromatography using a Nucleosil 100
C18 column (5 micron, 150U4.6 mm; Alltech Associates, Inc., Deer-
¢eld, IL, USA) and a gradient system. The two mobile phase solvents
were 25 mM KH2PO4 (pH 4.9) and 100% acetonitrile. The long-chain
acyl-CoA esters were eluted by a linear gradient [23]. Palmitoyl-CoA
was identi¢ed using a palmitoyl-CoA standard. Samples with the ap-
propriate retention time were recovered and analyzed by scintillation
counting. Values for palmitoyl-CoA were corrected for di¡erences in
recovery of the radiolabeled internal control. Cell number and cellular
protein were not di¡erent between control and Fas-treated groups.
2.9. Carnitine measurements in whole cells
Carnitine content in Jurkat cells was determined using the radio-
isotopic assay of McGarry [24] and McMillin [25] with modi¢cation.
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Brie£y, 0.5 ml cell suspension containing 2.5^3.0U108 cells was pre-
cipitated in 0.3 ml 10% HClO4. After centrifugation, pellets were
washed in 0.3 ml 10% HClO4 by vortexing. Two fractions were com-
bined and bu¡ered with Tris (¢nal concentration 115 mM), neutral-
ized with KOH to pH 7.8 and placed on ice for 60 min to precipitate
KClO4. After centrifugation, the KClO4 pellets were washed in 0.2 ml
115 mM ice-cold Tris bu¡er. Two supernatants were combined and
aliquoted into triplicate samples. Each sample had an equivalent of
2.5^4.0 mg of cell protein. Reaction was started by adding 3 U carni-
tine acetyltransferase (Boehringer Mannheim) to the mixture contain-
ing 0.05 WCi [3H]acetyl-CoA (speci¢c activity (S.A.) 200 mCi/mmol,
American Radiolabeled Chemicals, Inc.), 100 WM acetyl-CoA. Sam-
ples were incubated at room temperature for 2 h. The reaction was
stopped by adding 500 Wl stirred slurry of AG1-X8 resin (chloride
form, Bio-Rad). The mixture was vortexed and placed on ice. This
procedure was repeated three times at 5 min intervals. All samples
were centrifuged at 4‡C. A 0.1 ml supernatant was used for scintilla-
tion counting. An enzyme blank was included to correct for non-
speci¢c radioactivity in the supernatants. A carnitine standard curve
(2.5, 5.0, 10 WM) was included with each experiment.
2.10. Detection of palmitoylcarnitine formation during apoptosis
A 2 ml culture of Jurkat cells at a density of 1U106 cells/ml was
transferred into each well of a culture plate, then 10 WCi [3H]carnitine
(S.A. 80 Ci/mmol, American Radiolabeled Chemicals, Inc.) was
added. After 3 h of labeling, anti-Fas antibody (500 ng/ml) was added
to one well and incubated for 1 h to induce apoptosis. At this time,
both control and apoptotic cells were collected and washed once in
PBS. After centrifugation, cells were resuspended in 0.2 ml PBS. To
extract palmitoylcarnitine, 0.4 ml water-saturated n-butanol was
added to each sample and vortexed for 5 min. Samples were centri-
fuged to separate the butanol and aqueous phases. Butanol fractions
were concentrated to approximately 50 Wl, loaded on a thin layer
chromatography (TLC) plate (Silica Gel 60, 200 micron, Fisher Sci-
enti¢c) and resolved in chloroform:methanol:water (65:25:4). Results
were detected by autoradiography.
3. Results
3.1. E¡ect of L-carnitine on Fas-induced apoptosis in Jurkat
cells
To determine if L-carnitine could protect against Fas-medi-
ated apoptosis, Jurkat cells were induced to undergo apopto-
sis with Fas ligation in the presence or absence of increasing
concentrations of L-carnitine. After 4 h, cells were harvested
and apoptosis was scored by changes in nuclear morphology.
L-Carnitine suppressed apoptosis in a dose-dependent fashion
(Table 1) consistent with inhibition of activated DEVD-pNA-
cleaving caspases (Fig. 1A). In addition, Western analysis
using caspase 2 as a marker for apoptosis showed that carni-
tine inhibited caspase 2 processing (Fig. 1B), suggesting that
L-carnitine is acting upstream of caspase 2 cleavage.
3.2. L-Carnitine inhibits the activity of recombinant caspase 3
We wondered whether the inhibition of caspase 2 cleavage
by L-carnitine resulted from the inhibition of an upstream
caspase 2 activator. It has been reported that caspase 2 may
be cleaved by caspase 3 [26] and as a result, we tested whether
carnitine was acting at this level. Carnitine inhibited the abil-
ity of recombinant caspase 3 to cleave the native protein sub-
strate caspase 2 in cell lysates (Fig. 1C). We compared L-car-
nitine to other biologically relevant quaternary amines,
including D-carnitine, betaine and trimethyllysine. We found
that L-carnitine was a potent inhibitor of recombinant caspase
3, followed by trimethyllysine and D-carnitine (Fig. 1D).
3.3. E¡ect of palmitoylcarnitine on the activity of recombinant
caspases 3 and 7
Caspase activity is enhanced by CHAPS, which is a quater-
nary amine zwitterion with a long hydrophobic side chain.
Palmitoylcarnitine is also a quaternary amine zwitterion
with a hydrophobic side chain. We evaluated whether a car-
nitine ester of either a short-chain or a long-chain fatty acid
(acetate and palmitate, respectively) would enhance caspase
activity. The inhibitory e¡ects of carnitine revealed a steep
dose^response curve, with minimal inhibition at 1 mM, slight
inhibition at 3 mM and nearly full inhibition at 5 mM. We
found that palmitoylcarnitine, but not acetylcarnitine, in-
creased the activity of recombinant caspase 3 (Fig. 2A) and
caspase 7 (data not shown), showing a maximal e¡ect at 50
WM.
3.4. L-Carnitine and palmitoylcarnitine have antagonistic e¡ects
The opposing e¡ects of carnitine and palmitoylcarnitine led
us to examine the ability of palmitoylcarnitine to reverse in-
hibition by carnitine of recombinant caspase 3. Palmitoylcar-
nitine was able to reverse this inhibition at a concentration of
10 WM (Fig. 2B). Furthermore, caspase 3 activity was partially
protected when the enzyme was preincubated with either pal-
mitoylcarnitine then carnitine added (Fig. 2B) or preincubated
with carnitine then palmitoylcarnitine added (not shown), sug-
gesting an antagonistic interaction.
We next examined the e¡ect of these compounds on cleav-
age of endogenous caspase substrates. The addition of palmi-
toylcarnitine to Jurkat cell lysates was not su⁄cient to cause
spontaneous activation of procaspases (data not shown). Im-
munoblot analysis of substrate cleavage in cell lysates mea-
sures an endpoint rather than enzymatic rate, and so we could
not detect an e¡ect of palmitoylcarnitine on the rate of acti-
vated caspases to process protein substrates. To further eval-
uate the antagonistic e¡ects of carnitine and palmitoylcarni-
tine, we looked at cleavage of human recombinant PARP by
recombinant caspase 3. As shown in Fig. 2C, 10 mM carnitine
inhibited the generation of the 85 kDa PARP fragment and
this was partially reversed by 50 WM palmitoylcarnitine (Fig.
3C).
3.5. Regulation of the activity of caspase 8 by L-carnitine and
palmitoylcarnitine
The preceding data showed that carnitine and palmitoylcar-
nitine regulated the activity of e¡ector caspases 3 and 7, im-
plying that in vivo they could regulate cleavage of endogenous
caspase substrates. We tested whether these compounds had
an e¡ect on the activity of an initiator caspase, caspase 8. Fig.
3A shows that carnitine at 5 mM inhibited the activity of
caspase 8, whereas palmitoylcarnitine stimulated the activity
of the enzyme. Since caspase 8 directly cleaves caspases 3 and
9 [27], we tested whether this would be a¡ected by incubation
Table 1
Nuclear morphology after Fas ligation





Jurkat cells were subjected to Fas ligation as described in the legend
to Fig. 1, and aliquots were analyzed for nuclear fragmentation
after acridine orange staining. Similar results were obtained in two
independent experiments.
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with either carnitine or palmitoylcarnitine. Fig. 3B shows that
5 mM carnitine inhibited the processing of caspase 3 and
caspase 9 by caspase 8, and that 10 WM palmitoylcarnitine
reversed the inhibition. Carnitine was also able to inhibit pro-
teolytic activation of caspase 9 mediated by Apaf-1, cyto-
chrome c and dATP (not shown).
3.6. Carnitine and palmitoyl-CoA levels during apoptosis
The foregoing observations demonstrated that carnitine and
palmitoylcarnitine could regulate caspase activity in vitro, and
that high levels of exogenous carnitine could attenuate caspase
2 processing and apoptosis. In order to determine if the bal-
ance of carnitine and palmitoylcarnitine is altered during ap-
optosis, we measured carnitine levels in Jurkat cells under-
going Fas-mediated apoptosis. We found that the carnitine
level decreased by 30% within 2 h after Fas ligation (Table 2).
Palmitoyl-CoA can be converted by CPT I to form palmi-
toylcarnitine, which we have shown favors caspase activity.
We measured palmitoyl-CoA levels and found them to be
signi¢cantly reduced during Fas-mediated apoptosis (Table
2). This observation is consistent with the notion that alter-
ations in fatty acid metabolism occur during apoptosis and
may modulate caspase activity.
3.7. Palmitoylcarnitine increases during apoptosis
It could be argued that the observed reductions in palmi-
toyl-CoA and free carnitine could represent losses from dying
cells. If, however, the reductions in carnitine and palmitoyl-
CoA are due to increased activity of CPT I, we would be able
to detect increased palmitoylcarnitine formation. We loaded
cells with [3H]carnitine and then subjected them to Fas liga-
tion for 1 h before lysing them and extracting palmitoylcarni-
tine for TLC. As shown in Fig. 4, an increase in the formation
of palmitoylcarnitine was evident as early as 60 min after Fas
ligation, consistent with the idea that there is a shift in the
ratio of carnitine to palmitoylcarnitine during apoptosis.
Fig. 1. E¡ect of L-carnitine on Fas-induced apoptosis in Jurkat cells. Jurkat cells were treated with anti-Fas antibody in the presence or absence
of increasing concentrations of L-carnitine and incubated at 37‡C for 4 h. The cells were lysed and whole cell lysates prepared as described in
Section 2. (A) Activation of DEVD-speci¢c caspases in whole cell lysates (100 Wg) was measured by cleavage of the synthetic peptide substrate
DEVD-pNA. The data shown are mean þ S.D. from a triplicate experiment representative of two di¡erent experiments. (B) 100 Wg proteins
were subjected to SDS^PAGE and Western analysis using anti-caspase 2 antibodies. The results shown are representative of two independent
experiments. (C) Inhibition of recombinant caspase 3 activity by L-carnitine. Di¡erent naturally occurring compounds (at a ¢nal concentration
of 5 mM) were preincubated for 15 min with 20 ng recombinant caspase 3 and then enzyme activity measured by DEVD-pNA cleavage.
1, none; 2, CHAPS; 3, betaine; 4, taurine; 5, trimethyllysine; 6, D-carnitine; 7, L-carnitine; 8, choline; 9, phosphorylcholine chloride. The data
shown are mean þ S.D. from a triplicate experiment representative of three independent experiments. (D) Jurkat cells were lysed by nitrogen
cavitation and S100 cytosols prepared as described in Section 2. 100 Wg protein samples were incubated with 20 ng of recombinant caspase 3
for 2 h at 37‡C in the presence or absence of 5 mM L-carnitine. 30 Wg protein was analyzed by immunoblotting with antibody to caspase 2.
The results shown are from one experiment representative of two independent experiments.
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Fig. 3. E¡ect of L-carnitine and palmitoylcarnitine on the activity of
recombinant caspase 8. (A) Di¡erent concentrations of L-carnitine
and palmitoylcarnitine were added to 200 ng of recombinant cas-
pase 8 and enzyme activities assayed as already described. The data
shown are mean þ S.D. from a triplicate experiment. (B) S100 cyto-
sols (100 Wg) were incubated with 20 ng of recombinant caspase 8
for 2 h at 37‡C in the presence or absence of 5 mM L-carnitine and
10 WM palmitoylcarnitine. 30 Wg proteins were analyzed by Western
blotting with anti-caspase 9 and anti-caspase 3 antibodies. 30 Wg of
protein was analyzed by Western blotting with anti-caspase 9 and
anti-caspase 3 antibodies. Arrows indicate cleaved products.
Fig. 2. E¡ect of L-carnitine and its acyl derivatives on the activities
of recombinant caspases. Di¡erent concentrations of L-carnitine,
acetylcarnitine and palmitoylcarnitine were added to 20 ng of (A)
recombinant caspase 3. Enzyme activities were then assayed as al-
ready described. (B) 20 ng of recombinant caspase 3 was incubated
with 50 WM palmitoylcarnitine for 10 min at room temperature then
increasing concentrations of carnitine added and enzyme activities
determined. The data shown are mean þ S.D. from triplicate experi-
ments done at least two di¡erent times. (C) Recombinant caspase 3
(20 ng) was preincubated with or without 50 WM palmitoylcarnitine
before addition of increasing concentrations of carnitine and 2 Wg
PARP. The mixtures were incubated at 37‡C for 25 min then the
samples subjected to SDS^PAGE and Western analysis. The results
shown are representative of three independent experiments.
Table 2
Alterations in the levels of carnitine and palmitoyl-CoA during Fas-
mediated apoptosis
Control (%) ( þ S.E.M.) P value
Carnitine (n = 4) 70 þ 9 6 0.05
Palmitoyl-CoA (n = 6) 58 þ 7 6 0.05
Carnitine and palmitoyl-CoA levels were determined in Jurkat cells
after 2 h incubation with anti-Fas antibody, or after 1^2 h incuba-
tion without antibody. Results are reported as percent of control
values. Control values for carnitine were 0.42 þ 0.03 nmol/mg of
cellular protein. Control values for palmitoyl-CoA were 198 þ 90
ng/108 cells. Apoptosis was determined, and only those experiments
in which apoptosis was less than 5% in control cells and greater
than 20% in Fas-ligated cells were included. Statistical signi¢cance
was determined by paired Wilcoxon rank-sum for palmitoyl-CoA
and by one-sample t-test for carnitine.
Fig. 4. E¡ect of Fas ligation on palmitoylcarnitine formation. Jur-
kat cells were loaded with [3H]carnitine for 3 h then resuspended in
fresh media with or without anti-Fas antibody. After 1 h, palmitoyl-
carnitine was extracted in butanol and resolved by TLC and de-
tected by autoradiography. Con : control; Fas : Fas-treated. This ex-
periment is representative of three. Palmitoylcarnitine (upper spots)
is increased after Fas ligation. Free carnitine remains at the origin,
and although butanol extraction does not quantitatively recover free
carnitine, relatively more free carnitine is detected in the control ex-
tracts than in the Fas-ligated cells, an observation which supports
the direct measurements of carnitine reported in Table 2.
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3.8. CPT I de¢cient ¢broblasts show resistance to
staurosporine-induced apoptosis
To test the possibility that CPT I may play an active role in
promoting caspase activation during apoptosis, we examined
the susceptibility to apoptosis in a ¢broblast cell line derived
from a patient with CPT I de¢ciency, compared to a normal
¢broblast line. Treatment of the ¢broblast cell lines with anti-
Fas antibody did not lead to apoptosis, as measured by cell
detachment, uptake of the YOPRO-1 dye and cleavage of
caspases. On the other hand, another inducer of apoptosis,
staurosporine, led to an increase in cell death as measured
by the same parameters. Incubation of wild type ¢broblasts
with 5 and 10 WM staurosporine for 12 h led to an increase in
the percentage of cell death, and this was signi¢cantly reduced
in CPT I de¢cient ¢broblasts (49% of wild type, n = 3,
P6 0.001 by ANOVA), consistent with our hypothesis that
conversion of carnitine to palmitoylcarnitine may enhance ap-
optosis.
4. Discussion
The results from this study suggest that caspases are subject
to regulation by non-peptide metabolites. Our data show that
carnitine can inhibit caspase activity at various points in the
Fas ligation pathway. It can inhibit the activity of an initiator
caspase, caspase 8, as well as the processing of caspase 9,
thereby e¡ectively inhibiting cleavage and activation of down-
stream caspases. Furthermore, carnitine also inhibited cleav-
age of caspase substrates by downstream caspases, making it a
general caspase inhibitor, at least blocking one aspect of ap-
optosis. The concentration of carnitine needed to inhibit cas-
pases is at the upper limits of levels seen in skeletal muscle
and probably exceeds the normal concentration in lympho-
cytes. However, the ¢nding that carnitine levels decrease dur-
ing Fas-mediated apoptosis suggests that the endogenous car-
nitine may play a regulatory role. Palmitoylcarnitine reversed
the inhibition by carnitine, and palmitoylcarnitine levels rose
early in apoptosis. The mechanism by which carnitine and
palmitoylcarnitine regulate caspase activity remains to be de-
termined. Although a number of quaternary amines have been
shown to be non-speci¢c inhibitors of various enzymes, the
ability of palmitoylcarnitine at a concentration of 10 WM to
reverse this inhibition suggests that the interaction is biolog-
ically relevant. Palmitoylcarnitine increases caspase activity at
concentrations as low as 1 WM, well below its critical micellar
concentration.
These ¢ndings suggest that CPT I, which converts the sub-
strates carnitine and palmitoyl-CoA into palmitoylcarnitine,
may be involved in regulation of apoptosis. Our results
show that levels of carnitine and palmitoyl-CoA decreased,
while palmitoylcarnitine formation was increased. Addition-
ally, palmitoylcarnitine reversed the inhibition of caspase ac-
tivity by carnitine, which may suggest that under physiological
conditions, the changes in the ratios of these metabolites
may be important in regulating caspase activity. Accumula-
tion of long-chain acyl carnitines has been reported in cardiac
tissue during ischemia [28,29], most likely due to a cessa-
tion of L-oxidation. We suggest that this shift in the balance
of carnitine and its acyl derivatives may contribute to apopto-
sis.
The possible involvement of CPT I in apoptosis was ini-
tially discovered based on the enhanced expression of its
mRNA in the murine hematopoietic cell line, LyD9, when
deprived of interleukin-3 [30], and also indirectly by its asso-
ciation with Bcl-2 [31]. Paumen et al. used etomoxir to inhibit
CPT I, which they found increased apoptosis [31]. However,
they used a concentration of etomoxir (200 WM) that would
also inhibit CPT II, thereby preventing conversion of acylcar-
nitines back to acyl-CoA for L-oxidation [32,33]. Since they
did not measure the relevant metabolites, it is impossible to
conclude whether palmitoylcarnitine levels decreased or re-
mained unchanged in their model. It was recently reported
that carnitine inhibits an acid sphingomyelinase, thereby pre-
venting ceramide generation [34,35]. Further investigation of
fatty acid metabolism changes during apoptosis is needed to
clarify the role of CPT I in regulating apoptosis.
The use of a simple metabolite like carnitine as an anti-
apoptotic agent is very attractive since it is likely to be rela-
tively non-toxic compared to synthetic inhibitors. The chemo-
therapeutic e¡ects of L-carnitine have already been demon-
strated in AIDS and Alzheimer’s disease and ischemic injury
[10^12]. It is worthwhile understanding how palmitoylcarni-
tine and carnitine may regulate apoptotic events under phys-
iological conditions and in pathophysiologic states. For in-
stance, during myocardial ischemia, palmitoylcarnitine levels
increase greatly. We suggest that this would tend to favor
caspase activation, leading to apoptosis. The use of CPT I
inhibitors such as etomoxir should be re-evaluated in view
of alteration of the ratio of carnitine to palmitoylcarnitine
and consequent modulation of caspase activity. This may ex-
plain one bene¢cial aspect of etomoxir therapy for heart fail-
ure [36].
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